Charts

Rodney Varner, CEO of Genprex, Inc. ("Genprex" or the "Company") (Nasdaq: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today commended The U.S. Food and Drug Administration's (FDA) initiative that aims to expedite the development of gene therapies for patients with rare diseases. As such, the FDA announced that it will support using biomarkers as substitutes for other biological indicators in gene therapy clinic

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the Company's Chief Manufacturing and Technology Officer, Hemant Kumar, Ph.D., will participate in the upcoming Bioprocessing Summit Europe Conference taking place March 14-16, 2023 in Barcelona, Spain.

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the Company's participation in the following upcoming investor and industry conferences to be held in March 2023.

U.S. stocks traded higher toward the end of trading, with the NASDAQ Composite gaining around 100 points on Monday. The Dow traded up ...

Gainers Lucira Health, Inc. (NASDAQ: LHDX) jumped 354% to $0.6369 after the company announced FDA authorization for its at-home ...

Gainers Lucira Health (NASDAQ:LHDX) stock increased by 255.5% to $0.5 during Monday's regular session. The current volume of 208.4 ...

U.S. stocks traded higher midway through trading, with the NASDAQ Composite gaining around 80 points on Monday. The Dow traded up ...

Genprex Inc (NASDAQ: GNPX) shares are trading lower by 19.12% to $1.10 during Monday's pre-market session. The company announced a ...

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced it has entered into a securities purchase agreement with a single, healthcare-focused institutional investor for the purchase and sale of 3,809,524 shares of its common stock together with warrants to purchase up to 3,809,524 shares of common stock at a combined purchase price of $1.05 per share and a

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Teladoc (TDOC) stock is on the move Thursday after getting an upgrade from SVB Securities even after a poor earnings report. The post TDOC Stock Alert: What to Know as SVB Securities Upgrades Teladoc appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today It doesn’t matter if you have $500 or $5 million. Do this now. Massive Bear Market “Divergence Event” Ahead… And The #1 Way to Play It

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Genprex (GNPX) stock is on the move Thursday after providing investors with an update on a clinical trial of its diabetes treatment. The post Genprex (GNPX) Stock Moves on Promising Diabetes Treatment Data appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today It doesn’t matter if you have $500 or $5 million. Do this now. Massive Bear Market “Divergence Event” Ahead… And The #1 Way to Play It

Gainers Windtree Therapeutics, Inc. (NASDAQ: WINT) rose 24% to $0.31 in pre-market trading. Windtree Therapeutics shares jumped ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips We're starting off the day with a look at all the biggest pre-market stock movers traders need to know about on Thursday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today It doesn’t matter if you have $500 or $5 million. Do this now. Massive Bear Market “Divergence Event” Ahead… And The #1 Way to Play It

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that data highlighting the potential of Genprex's gene therapy for Type 1 diabetes is being presented by its research collaborators at the University of Pittsburgh (Pitt) at the 16th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2023) taking place February 22-25, 20

Upgrades According to B of A Securities, the prior rating for Flowserve Corp (NYSE:FLS) was changed from Neutral to Buy. Flowserve ...

Gainers Swvl Holdings Corp. (NASDAQ: SWVL) surged 133% to $0.3218. Swvl recently announced the commencement of a strategic review ...

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced it has entered into an exclusive license agreement (the Agreement) with the University of Pittsburgh (Pitt), granting Genprex a worldwide, exclusive license to a patent application and related technology and a worldwide, non-exclusive license to use certain related know-how, all related to gene therap

Gainers Vivos Therapeutics, Inc. (NASDAQ: VVOS) shares surged 204% to $2.25 after the company announced it received FDA 510(k) ...

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators at the University of Pittsburgh will present preclinical data highlighting the therapeutic potential of Genprex's gene therapy for Type 1 diabetes at the 16th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2023) being held February 22-

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced it has entered into an exclusive license agreement (the Agreement) with

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the Safety Review Committee (SRC) has approved continuation to the third and final cohort in the dose escalation Phase 1 portion of the Acclaim-1 Phase 1/2 clinical trial of REQORSA® in combination with Tagrisso® (osimertinib) to treat late-stage non-small cell lung cancer (NSCLC). In 2020, the c

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its Executive Vice President, General Counsel and Chief Strategy Officer, Catherine Vaczy, will be providing an overview of the Company's gene therapies for cancer and diabetes at the following investor conference in December 2022.

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the Company's participation in the following upcoming investor and industry conferences to be held in October 2022.

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its Chief Financial Officer, Ryan Confer, will be providing a virtual overview of the Company's gene therapies for cancer and diabetes at the following investor conference in September 2022.

Gainers Kiromic BioPharma (NASDAQ:KRBP) stock moved upwards by 83.1% to $0.69 during Friday's after-market session. Trading volume ...

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the United States Patent and Trademark Office (USPTO) has granted Genprex U.S. Patent No: 11,278,592 B2. The patent covers methods of using REQORSATM Immunogene Therapy in conjunction with immune checkpoint inhibitors, through 2038.

Gainers Magic Empire Global Limited (NASDAQ: MEGL) shares jumped 115.7% to close at $17.73 on volatility following the ...

Gritstone bio (NASDAQ: GRTS) announced that interim results from the Phase 1/2 trial of GRANITE, its individualized, vaccine-based ...

Gainers Sunrise New Energy Co. Ltd. (NASDAQ: EPOW) shares jumped 118.2% to $4.4948. Sunrise New Energy said that the company ...

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the Safety Review Committee (SRC) has approved continuation of the Acclaim-1 Phase 1/2 clinical trial of REQORSA™ in combination with Tagrisso® (osimertinib) to treat late-stage non-small cell lung cancer (NSCLC) following a review of the first cohort of patients in the Phase 1 portion of the tri

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that Company manufacturing leadership will present sessions on cutting edge topics in lipid-based nanoparticle delivery systems at the upcoming Next Generation Lipid-Based Nanoparticles Delivery Summit taking place from July 19-21, 2022 in Boston.

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the Company's participation in the following upcoming investor and industry conferences to be held in June 2022.

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its President and Chief Executive Officer, Rodney Varner, will be providing a virtual overview of the Company's gene therapies for cancer and diabetes to investors at the following conference in May 2022.

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its Chief Medical Officer, Mark Berger, M.D., will be featured as an expert panelist at the 33rd Annual Cancer Progress Conference, taking place virtually May 10-12, 2022.

Gainers Sonoma Pharmaceuticals (NASDAQ:SNOA) shares rose 50.7% to $4.01 during Tuesday's pre-market session. The ...

Genprex announces it has opened its Acclaim-2 clinical trial for patient enrollment.

Genprex announces participation in March conferences.

Genprex announces the dosing of its first patient in its Acclaim-1 clinical trial in non-small cell lung cancer

Genprex announces participation in February conferences.

Preclinical data finds that Genprex's ONCOPREX Nanoparticle Delivery System may be a potential platform for colon cancer

Gainers Exicure, Inc. (NASDAQ: XCUR) rose 41.1% to $0.23 in pre-market trading after gaining around 4% on Tuesday. Barfresh Food ...

Gainers Singularity Future Technology Ltd. (NASDAQ: SGLY) shares rose 25.9% to settle at $5.01 on Thursday. MedAvail Holdings, ...

Genprex announced a plan to accelerate the opening of clinical trial sites for the Acclaim-1 clinical trial.